Gemifloxacin for community-acquired pneumonia

Bibliography

• File TM. Community-acquired pneumonia. Lancet 2003;362:1991-2001
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
   Google Scholar
• ATS/IDSA. Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Doern GV, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997 – 1999. Clin Infect Dis 2001;32(Suppl 2):81-93
   Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN; The Alexander Project Group. The Alexander Project 1998 – 2000: susceptibility of pathogens isolated from community-acquired respiratory tract infections to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46
   PubMedGoogle Scholar
• Ferrara AL. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection 2005;33:106-14
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80
   PubMed Web of Science ®Google Scholar
• Lode HM. Managing community-acquired pneumonia: a European perspective. Respir Med 2007;101:1864-73
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60
   PubMed Web of Science ®Google Scholar
• File TM Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 2004;39(Suppl 3):159-64
   PubMed Web of Science ®Google Scholar
• Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-9
   PubMed Web of Science ®Google Scholar
• Anderson KB, Tan JS, File TM Jr, et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003;37:376-81
   PubMed Web of Science ®Google Scholar
• Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal respiratory tract infections. Eur Respir J 2002;20(Suppl 36):3-8
   Google Scholar
• Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: In vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2005;25:717-40
   PubMed Web of Science ®Google Scholar
• Brenwald NP, Appelbaum P, Davies T, Gill MJ. Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Clin Microbiol Infect 2003;9:140-3
   PubMed Web of Science ®Google Scholar
• Morrissey I, George JT. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. J Antimicrob Chemother 2000;45(Suppl S1):101-6
   PubMed Web of Science ®Google Scholar
• Heaton VJ, Ambler JE, Fisher LM. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother 2000;44:3112-17
   PubMed Web of Science ®Google Scholar
• Jones RN, Pfaller MA, Erwin ME. Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas. Int J Antimicrob Agents 2000;15:227-30
   PubMed Web of Science ®Google Scholar
• Koeth LM, Jacobs MR, Bajaksouzian S, et al. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999 – 2000. Int J Antimicrob Agents 2002;19:33-7
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: document M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute; 2005
   Google Scholar
• Lowe MN, Lamb HM. Gemifloxacin. Drugs 2000;59:1137-47
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007;44:79-86
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003;17:529-43
   PubMed Web of Science ®Google Scholar
• Owens RC Jr, Bhavnani SM, Ambrose PG. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2005;51:45-9
   PubMed Web of Science ®Google Scholar
• Ball P, File TM, Twynholm M, Henkel T; the 061 Study Group. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents 2001;18:19-27
   PubMed Web of Science ®Google Scholar
• File TM Jr, Schlemmer B, Garau J, et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 2001;48:67-74
   PubMed Web of Science ®Google Scholar
• Lode H, File TM Jr, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002;24:1915-36
   PubMed Web of Science ®Google Scholar
• Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98:708-20
   PubMed Web of Science ®Google Scholar
• File TM, Mandell LA, Tillotson G, et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007;60:112-20
   PubMed Web of Science ®Google Scholar
• Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005;65:949-91
   PubMed Web of Science ®Google Scholar
• Ball P, Mandell L, Patou G, et al. A respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004;23:421-9
   PubMed Web of Science ®Google Scholar